Evidence map›Paper›PMID 36448795›Full record

ArticleAntimicrobial agents and chemotherapy2022

Johanne Blais, Charles R Dean, Guillaume Lapointe, Jennifer A Leeds, Sylvia Ma, Laura Morris, Heinz E Moser, Colin S Osborne, Katherine R Prosen, Daryl Richie and 5 more

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Microorganisms · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Johanne BlaisNovartis Institutes for BioMedical Research, Emeryville, California, USA.ORCID 0000-0001-8139-8855
Charles R DeanNovartis Institutes for BioMedical Research, Emeryville, California, USA.ORCID 0000-0001-9858-9818
Guillaume LapointeNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Jennifer A LeedsNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Sylvia MaNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Laura MorrisNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Heinz E MoserNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Colin S OsborneNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Katherine R ProsenNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Daryl RichieNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Colin SkepperNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Katherine ThompsonNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Jason VoNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Qin YueNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Alexey RivkinNovartis Institutes for BioMedical Research, Emeryville, California, USA.
Novartis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CUO246, a novel DNA gyrase/topoisomerase IV inhibitor, is active

Indexed as

DNA GyraseDNA Topoisomerase IVAnimalsAnti-Bacterial AgentsDNA, BacterialMiceMicrobial Sensitivity TestsStaphylococcus aureusTopoisomerase II InhibitorsAnti-Bacterial AgentsDNA, BacterialDNA GyraseDNA Topoisomerase IVTopoisomerase II InhibitorsCUO246DNA gyrasein vitro activityin vivo efficacytopoisomerase IV

Identifiers

PMID36448795
PMCPMC9765007
OpenAlexW4310398099

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.